The National Institutes of Health (NIH) is offering the Biomedical Research, Development, and Growth to Spur the Acceleration of New Technologies (BRDG-SPAN) Pilot Program (RC3) through its Recovery Act funding. This grant aims to address the critical ‘Valley of Death’ funding gap, supporting later-stage research activities essential for transitioning promising biomedical innovations from R&D to market commercialization. The program seeks to accelerate the development of products and services that improve human health, advance the NIH mission, and generate economic stimulus. Utilizing the RC3 grant mechanism, NIH anticipates committing at least $35 million to make a minimum of 10 awards in fiscal year 2010. Projects demonstrating high commercial potential, addressing underserved needs, or securing independent third-party investment may receive funding priority.
Opportunity ID: 47740
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-OD-09-008 |
| Funding Opportunity Title: | Recovery Act Limited Competition: Biomedical Research, Development, and Growth to Spur the Acceleration of New Technologies (BRDG-SPAN) Pilot Program (RC3) |
| Opportunity Category: | Other |
| Opportunity Category Explanation: | Recovery Act |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health Recovery Act |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.701 — Trans-NIH Recovery Act Research Support |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 3 |
| Posted Date: | Jun 02, 2009 |
| Last Updated Date: | Jul 24, 2009 |
| Original Closing Date for Applications: | Sep 01, 2009 |
| Current Closing Date for Applications: | Sep 01, 2009 |
| Archive Date: | Oct 02, 2009 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $1,000,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | For profit organizations other than small businesses Small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: This FOA encourages submissions by United-States for-profit enterprises/commercial organizations doing a majority of their business in the United States. Applications received under this FOA may be given funding priority if the applicant is associated with an enterprise/commercial organization that is of small size (e.g., 500 or fewer employees), and/or of limited resources, such as an early-stage company, and/or one positioned for receiving funding or in-kind support from a third-party investor and/or strategic partner. The applicant United States institution/organization must be located in the 50 states, territories and possessions of the U.S., Commonwealth of Puerto Rico, Trust Territory of the Pacific Islands, or District of Columbia. NIH encourages applications from all interested organizations/institutions, including those from Institutional Development Award (IDeA) states. Foreign organizations/institutions are not permitted as the applicant organization. If the application includes subcontractors, the applicant for-profit enterprise/commercial organization must be substantially involved in the R and D, with a leadership role in the project and defining the research agenda. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | Purpose. This Funding Opportunity Announcement (FOA), supported by funds provided to the NIH under the American Recovery and Reinvestment Act of 2009 (Recovery Act or ARRA), Public Law 111-5, solicits grant applications for a new initiative called Biomedical Research, Development, and Growth to Spur the Acceleration of New Technologies (BRDG-SPAN) Pilot Program (RC3). The purpose of this pilot program is to address the funding gap between promising research and development (R and D) and transitioning to the market — often called the Valley of Death — by contributing to the critical funding needed by applicants to pursue the next appropriate milestone(s) toward ultimate commercialization; i.e., to carry out later stage research activities necessary to that end. This program aims to accelerate the transition of research innovations and technologies toward the development of products or services that will improve human health, help advance the mission of NIH and its Institutes and Centers (ICs), and create significant value and economic stimulus. This program also aims to foster partnerships among a variety of research and development (R and D) collaborators working toward these aims. Mechanism of Support. This FOA will utilize the RC3 grant mechanism. Funds Available and Anticipated Number of Awards. Contingent upon the submission of a sufficient number of scientifically meritorious applications, NIH intends to commit at least $35 million in response to this FOA. We anticipate that at least 10 awards will be made in fiscal year 2010, pending the number and quality of applications and availability of funds. As a pilot, an evaluation will be necessary before any reissuance of this FOA; any reissuance is also predicated on funds availability. Applications received under this FOA may be given funding priority if the project is deemed to have high commercial potential to be developed into a product or service as indicated by the underserved need being addressed, the lack of alternative resources in the market and/or the applicants ability to secure funding or in-kind support from an independent third-party investor and/or strategic partner. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-09-008.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| This is to notify potential applicants of Important Registration Reminders for Businesses Submitting in Response to New Recovery Act Funding Opportunity Announcements. See Notice NOT-OD-09-126 for details at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-09-126.html. | Jul 24, 2009 | |
| Modified to add Recovery Act to the explanation field | Jul 24, 2009 | |
| Jun 02, 2009 |
DISPLAYING: Synopsis 3
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-OD-09-008 |
| Funding Opportunity Title: | Recovery Act Limited Competition: Biomedical Research, Development, and Growth to Spur the Acceleration of New Technologies (BRDG-SPAN) Pilot Program (RC3) |
| Opportunity Category: | Other |
| Opportunity Category Explanation: | Recovery Act |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health Recovery Act |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.701 — Trans-NIH Recovery Act Research Support |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 3 |
| Posted Date: | Jun 02, 2009 |
| Last Updated Date: | Jul 24, 2009 |
| Original Closing Date for Applications: | Sep 01, 2009 |
| Current Closing Date for Applications: | Sep 01, 2009 |
| Archive Date: | Oct 02, 2009 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $1,000,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | For profit organizations other than small businesses Small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: This FOA encourages submissions by United-States for-profit enterprises/commercial organizations doing a majority of their business in the United States. Applications received under this FOA may be given funding priority if the applicant is associated with an enterprise/commercial organization that is of small size (e.g., 500 or fewer employees), and/or of limited resources, such as an early-stage company, and/or one positioned for receiving funding or in-kind support from a third-party investor and/or strategic partner. The applicant United States institution/organization must be located in the 50 states, territories and possessions of the U.S., Commonwealth of Puerto Rico, Trust Territory of the Pacific Islands, or District of Columbia. NIH encourages applications from all interested organizations/institutions, including those from Institutional Development Award (IDeA) states. Foreign organizations/institutions are not permitted as the applicant organization. If the application includes subcontractors, the applicant for-profit enterprise/commercial organization must be substantially involved in the R and D, with a leadership role in the project and defining the research agenda. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | Purpose. This Funding Opportunity Announcement (FOA), supported by funds provided to the NIH under the American Recovery and Reinvestment Act of 2009 (Recovery Act or ARRA), Public Law 111-5, solicits grant applications for a new initiative called Biomedical Research, Development, and Growth to Spur the Acceleration of New Technologies (BRDG-SPAN) Pilot Program (RC3). The purpose of this pilot program is to address the funding gap between promising research and development (R and D) and transitioning to the market — often called the Valley of Death — by contributing to the critical funding needed by applicants to pursue the next appropriate milestone(s) toward ultimate commercialization; i.e., to carry out later stage research activities necessary to that end. This program aims to accelerate the transition of research innovations and technologies toward the development of products or services that will improve human health, help advance the mission of NIH and its Institutes and Centers (ICs), and create significant value and economic stimulus. This program also aims to foster partnerships among a variety of research and development (R and D) collaborators working toward these aims. Mechanism of Support. This FOA will utilize the RC3 grant mechanism. Funds Available and Anticipated Number of Awards. Contingent upon the submission of a sufficient number of scientifically meritorious applications, NIH intends to commit at least $35 million in response to this FOA. We anticipate that at least 10 awards will be made in fiscal year 2010, pending the number and quality of applications and availability of funds. As a pilot, an evaluation will be necessary before any reissuance of this FOA; any reissuance is also predicated on funds availability. Applications received under this FOA may be given funding priority if the project is deemed to have high commercial potential to be developed into a product or service as indicated by the underserved need being addressed, the lack of alternative resources in the market and/or the applicants ability to secure funding or in-kind support from an independent third-party investor and/or strategic partner. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-09-008.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-OD-09-008 |
| Funding Opportunity Title: | Recovery Act Limited Competition: Biomedical Research, Development, and Growth to Spur the Acceleration of New Technologies (BRDG-SPAN) Pilot Program (RC3) |
| Opportunity Category: | Other |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health Recovery Act |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.701 — Trans-NIH Recovery Act Research Support |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Jul 24, 2009 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Sep 01, 2009 |
| Archive Date: | Oct 02, 2009 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $1,000,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | For profit organizations other than small businesses Small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: This FOA encourages submissions by United-States for-profit enterprises/commercial organizations doing a majority of their business in the United States. Applications received under this FOA may be given funding priority if the applicant is associated with an enterprise/commercial organization that is of small size (e.g., 500 or fewer employees), and/or of limited resources, such as an early-stage company, and/or one positioned for receiving funding or in-kind support from a third-party investor and/or strategic partner. The applicant United States institution/organization must be located in the 50 states, territories and possessions of the U.S., Commonwealth of Puerto Rico, Trust Territory of the Pacific Islands, or District of Columbia. NIH encourages applications from all interested organizations/institutions, including those from Institutional Development Award (IDeA) states. Foreign organizations/institutions are not permitted as the applicant organization. If the application includes subcontractors, the applicant for-profit enterprise/commercial organization must be substantially involved in the R and D, with a leadership role in the project and defining the research agenda. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | Purpose. This Funding Opportunity Announcement (FOA), supported by funds provided to the NIH under the American Recovery and Reinvestment Act of 2009 (Recovery Act or ARRA), Public Law 111-5, solicits grant applications for a new initiative called Biomedical Research, Development, and Growth to Spur the Acceleration of New Technologies (BRDG-SPAN) Pilot Program (RC3). The purpose of this pilot program is to address the funding gap between promising research and development (R and D) and transitioning to the market — often called the Valley of Death — by contributing to the critical funding needed by applicants to pursue the next appropriate milestone(s) toward ultimate commercialization; i.e., to carry out later stage research activities necessary to that end. This program aims to accelerate the transition of research innovations and technologies toward the development of products or services that will improve human health, help advance the mission of NIH and its Institutes and Centers (ICs), and create significant value and economic stimulus. This program also aims to foster partnerships among a variety of research and development (R and D) collaborators working toward these aims. Mechanism of Support. This FOA will utilize the RC3 grant mechanism. Funds Available and Anticipated Number of Awards. Contingent upon the submission of a sufficient number of scientifically meritorious applications, NIH intends to commit at least $35 million in response to this FOA. We anticipate that at least 10 awards will be made in fiscal year 2010, pending the number and quality of applications and availability of funds. As a pilot, an evaluation will be necessary before any reissuance of this FOA; any reissuance is also predicated on funds availability. Applications received under this FOA may be given funding priority if the project is deemed to have high commercial potential to be developed into a product or service as indicated by the underserved need being addressed, the lack of alternative resources in the market and/or the applicants ability to secure funding or in-kind support from an independent third-party investor and/or strategic partner. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-09-008.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-OD-09-008 |
| Funding Opportunity Title: | Recovery Act Limited Competition: Biomedical Research, Development, and Growth to Spur the Acceleration of New Technologies (BRDG-SPAN) Pilot Program (RC3) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health Recovery Act |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.701 — Trans-NIH Recovery Act Research Support |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jun 02, 2009 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Sep 01, 2009 |
| Archive Date: | Oct 02, 2009 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $1,000,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | For profit organizations other than small businesses Small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: This FOA encourages submissions by United-States for-profit enterprises/commercial organizations doing a majority of their business in the United States. Applications received under this FOA may be given funding priority if the applicant is associated with an enterprise/commercial organization that is of small size (e.g., 500 or fewer employees), and/or of limited resources, such as an early-stage company, and/or one positioned for receiving funding or in-kind support from a third-party investor and/or strategic partner. The applicant United States institution/organization must be located in the 50 states, territories and possessions of the U.S., Commonwealth of Puerto Rico, Trust Territory of the Pacific Islands, or District of Columbia. NIH encourages applications from all interested organizations/institutions, including those from Institutional Development Award (IDeA) states. Foreign organizations/institutions are not permitted as the applicant organization. If the application includes subcontractors, the applicant for-profit enterprise/commercial organization must be substantially involved in the R and D, with a leadership role in the project and defining the research agenda. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | Purpose. This Funding Opportunity Announcement (FOA), supported by funds provided to the NIH under the American Recovery and Reinvestment Act of 2009 (Recovery Act or ARRA), Public Law 111-5, solicits grant applications for a new initiative called Biomedical Research, Development, and Growth to Spur the Acceleration of New Technologies (BRDG-SPAN) Pilot Program (RC3). The purpose of this pilot program is to address the funding gap between promising research and development (R and D) and transitioning to the market — often called the Valley of Death — by contributing to the critical funding needed by applicants to pursue the next appropriate milestone(s) toward ultimate commercialization; i.e., to carry out later stage research activities necessary to that end. This program aims to accelerate the transition of research innovations and technologies toward the development of products or services that will improve human health, help advance the mission of NIH and its Institutes and Centers (ICs), and create significant value and economic stimulus. This program also aims to foster partnerships among a variety of research and development (R and D) collaborators working toward these aims. Mechanism of Support. This FOA will utilize the RC3 grant mechanism. Funds Available and Anticipated Number of Awards. Contingent upon the submission of a sufficient number of scientifically meritorious applications, NIH intends to commit at least $35 million in response to this FOA. We anticipate that at least 10 awards will be made in fiscal year 2010, pending the number and quality of applications and availability of funds. As a pilot, an evaluation will be necessary before any reissuance of this FOA; any reissuance is also predicated on funds availability. Applications received under this FOA may be given funding priority if the project is deemed to have high commercial potential to be developed into a product or service as indicated by the underserved need being addressed, the lack of alternative resources in the market and/or the applicants ability to secure funding or in-kind support from an independent third-party investor and/or strategic partner. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-09-008.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 93.701 | ADOBE-FORMS-A | Adobe-Forms-A | PKG00012425 | Aug 01, 2009 | Sep 18, 2009 | View |
Package 1
Mandatory forms
47740 RR_SF424-1.1.pdf
47740 RR_KeyPersonExpanded-1.1.pdf
47740 RR_OtherProjectInfo-1.1.pdf
47740 RR_PerformanceSite-1.1.pdf
47740 RR_Budget-1.1.pdf
47740 PHS398_CoverPageSupplement-1.1.pdf
47740 PHS398_ResearchPlan-1.1.pdf
47740 PHS398_Checklist-1.1.pdf
Optional forms
47740 PHS398_CoverLetter-1.1.pdf
47740 RR_SubawardBudget-1.2.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
